In August of 2018, the U.S. Environmental Protection Agency (EPA) released its updated National Air Toxics Assessment(NATA). The NATA is a screening tool that that the EPA uses to determine potential health risks, including cancer, that can come from breathing hazardous air pollutants. The data contained in the updated NATA actually came from air samples taken in 2014. One of the pollutants tested for was ethylene oxide. According to the EPA, if the cancer risk to an individual is no higher than 1 in 10,000 (or 100 in 1 million), then the risk is “acceptable.” Continue reading “HIGH CANCER RISK FROM ETHYLENE OXIDE EMISSIONS”
A woman whose $1.2 million pelvic-mesh injury award was erased by an appeals court has asked the Texas Supreme Court to call off a final review, citing a settlement with device maker Johnson & Johnson.
Linda Batiste won $1.2 million in April 2014 over injuries allegedly caused by the TVT-O bladder sling. An appeals court overturned the trial award in November 2015 and Batiste quickly appealed to the Texas Supreme Court, where the case has been shelved ever since the two sides said last May that they’d reached a settlement in principle.
They asked the court Monday to dismiss the petition for review — despite still calling the deal an “agreement in principle.”
“The parties to this appeal have reached an agreement in principle to settle this case. Therefore, the parties file this joint request to dismiss the petition for review,” lawyers for Batiste and J&J said in the joint filing.
In the short motion, they also requested unspecified “general relief.”
TVT-O pelvic mesh is used to treat stress urinary incontinence. The Dallas appeals court had held in November 2015 that Batiste must show a link between an alleged defect — like the alleged propensity of the TVT-O’s heavyweight, small-pore mesh to erode — and her injuries, instead of just showing that injuries were caused by the device as a whole.
Representatives for the parties were not immediately available for comment.
Batiste had first requested that the state high court put the case on hold in May 2016, saying the parties had reached a settlement in principle but needed time to hammer out details and get them on paper. A status report from Jan. 31 of this year indicated that they’d made “significant progress” and asked for the last in a line of extensions.
Batiste had contended the appellate court wrongly required her to prove her injuries were caused by a specific defect, saying Texas courts are split on whether medical device cases are specifically exempt from a Texas product liability law that requires plaintiffs to isolate causation to a specific defect.
That’s a standard under which “it will be virtually impossible for any plaintiff to prevail on a product liability claim against a drug or device manufacturer in Texas,” Batiste had told the high court in her initial petition.
The Dallas appeals court said in November 2015 that while it’s undisputed that TVT-O can cause complications and it’s undisputed that Batiste suffered from those complications, the law of products liability doesn’t guarantee a product will be free of risk.
Batiste is represented by Tim Goss and Sara Turman-Vedral of Freese & Goss PLLC, Peter de la Cerda of Edwards & de la Cerda PLLC, Richard Capshaw of Capshaw & Associates, and David Matthews of Matthews and Associates.
Johnson & Johnson is represented by Stephen Brody and Charles Lifland of O’Melveny & Myers LLP and Scott Stolley of Cherry Petersen Landry Albert LLP.
The case is Batiste v. Johnson & Johnson et al., case number 15-0975, in the Supreme Court of Texas.
If you have suffered from Hernia Mesh Complications then click here to submit a free case evaluation and analysis. There are no fees unless we win your case.
On December 1, 2016, the Judicial Panel on Multidistrict Litigation (JPMDL) is holding a hearing in Washington, DC to hear arguments on whether to create a new Multi-District Litigation (MDL), to be known as MDL 2753, in order to consolidate lawsuits around the United States involving Atrium Medical Corp. polypropylene surgical mesh patches. Rather than bog down many federal district courts around the country with these cases, that are increasing in number on a weekly basis, the MDL consolidation allows one federal judge to preside over these cases, increasing judicial efficiency, while at the same time avoiding the risks of inconsistent rulings and other issues resulting from multiple rulings from many judges around the country. The likelihood of the MDL being created is strong because Atrium agreed in a brief filed on Nov. 1, 2016 that the MDL should be created and the cases should be assigned to US District Judge Landya B. McCafferty in Concord, New Hamshire.
Atrium markets the C-Qur surgical mesh for permanent abdominal wall reinforcement in hernia repair surgeries. Atrium claims that the C-Qur Mesh’s barrier coating, comprised of Omega-3 fatty acids, will reduce the risk of complications involving the patient’s intestines, including, pain, adhesions, and erosions, while at the same time helping the mesh better attach to the abdominal wall. However, plaintiffs claim in the lawsuits that the C-Qur mesh is defective and that there were inadequate warnings given on the complications associated with the mesh after implantation. The suits allege that the C-Qur mesh does not cut down on adhesions, but actually causes an inflammatory response that increases adhesion formation and it also impedes proper abdominal wall fixation for the mesh patch.
If you have suffered complications after a hernia surgery, please contact the experienced mesh lawyers at Dan Chapman & Associates, LLC ® for a free case evaluation. You can reach us by calling (800) 321-4477 or by going to our website at www.mesh411.com to learn more about these defective hernia mesh claims and whether you may be entitled to recover money for your injuries, harms and suffering.
Jury Finds Negligence With Johnson & Johnson
On October 27, 2016, Johnson & Johnson® lost a third straight jury trial to a woman claiming that she developed ovarian cancer after using Johnson & Johnson baby powder for many years. The St. Louis, MO jury awarded Deborah Giannecchini, age 62, an award of more than $70 million in damages. This verdict follows damages verdicts of $72 million and $55 million against J&J returned this year in the first two talc powder cases to go to trial in St. Louis. Both of the earlier verdicts are being appealed and J&J also has said it will appeal this third verdict.
One juror interviewed after the trial said J&J should have provided a warning label on the product to let consumers decide whether to use the talc powder. Juror Billie Ray of St. Louis said after the trial “it seemed like Johnson & Johnson didn’t pay attention.” She also said “it seemed like they didn’t care.” J&J has denied any link to talc use and ovarian cancer.
J&J is facing hundreds of claims in St. Louis state court. It is also facing about more suits in Los Angeles, CA and others in New Jersey by woman claiming to have developed ovarian cancer after long term use of the talc powder. However, a New Jersey state court judge last month threw out two J&J talc cases set for trial, finding inadequate scientific support for the cancer claims.
Our legal team is filing talc cases for women who have suffered from ovarian cancer after the use of talc powder products, such as Johnson’s Baby Powder® and Shower To Shower®. If you or a loved one used Johnson’s Baby Powder® or Shower To Shower® for more than 5 years and have developed ovarian cancer, please contact us for a free, no obligation, case evaluation.
Representatives are available 24/7 to take your call at (800)321-4477.